- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Prothena Corp. PLC Aktie
Verkaufen
Kaufen
Prothena Corp. PLC Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Prothena Corp. PLC Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,46 %
Intraday
-3,81 %
1 Woche
-1,16 %
1 Monat
-57,62 %
Seit Jahresbeginn
-61,70 %
1 Jahr
-68,18 %
3 Jahre
-7,84 %
5 Jahre
-27,97 %
10 Jahre
Wikifolio
Passender Service zu Prothena Corp. PLC
Webinar zu Prothena Corp. PLC
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)11,700-41,545
- Jahrestief / Hoch ($)11,700-41,545
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Prothena Corp. PLC
Keine Dividenden verfügbar
Termine von Prothena Corp. PLC
- Feb13Prothena Corp. PLCQ4 2024 Earnings Release
- Mai13Prothena Corp. PLCQ1 2025 Earnings Release
- Aug7Prothena Corp. PLCQ2 2025 Earnings Release
Beschreibung
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
